Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. doi: 10.1093/jnci/djn019. Epub 2008 Feb 26.

2.

Liquid compared with conventional cervical cytology: a systematic review and meta-analysis.

Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J.

Obstet Gynecol. 2008 Jan;111(1):167-77. doi: 10.1097/01.AOG.0000296488.85807.b3. Review.

PMID:
18165406
3.

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA.

Popul Health Metr. 2007 Oct 29;5:11.

4.

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.

Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference.

Am J Obstet Gynecol. 2007 Oct;197(4):346-55. Review.

PMID:
17904957
5.

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.

Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference.

Am J Obstet Gynecol. 2007 Oct;197(4):340-5. Review.

PMID:
17904956
6.

Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Insinga RP, Glass AG, Myers ER, Rush BB.

Med Decis Making. 2007 Jul-Aug;27(4):414-22. Epub 2007 Jun 21.

PMID:
17585005
7.

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.

Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M.

BMJ. 2007 Jul 7;335(7609):28. Epub 2007 May 21.

8.

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

FUTURE II Study Group.

N Engl J Med. 2007 May 10;356(19):1915-27.

9.
10.

Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects.

Smith RA, Cokkinides V, Eyre HJ.

CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104.

PMID:
17392386
11.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

12.

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors.

Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE; Gynecologic Cancer Advisory Group, Garcia F.

CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28. Review.

PMID:
17237032
13.

Chapter 10: New dimensions in cervical cancer screening.

Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/90-7. Epub 2006 Jun 23. Review.

PMID:
16950022
14.

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89. Review.

PMID:
16950021
15.

Chapter 19: Cost-effectiveness of cervical cancer screening.

Goldie SJ, Kim JJ, Myers E.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/164-70. Epub 2006 Jun 22. Review.

PMID:
16950004
16.

Cervical cancer screening, abnormal cytology management, and counseling practices in the United States.

Irwin K, Montaño D, Kasprzyk D, Carlin L, Freeman C, Barnes R, Jain N, Christian J, Wolters C.

Obstet Gynecol. 2006 Aug;108(2):397-409.

PMID:
16880312
17.

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.

Franco EL, Cuzick J, Hildesheim A, de Sanjosé S.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7. Epub 2006 Jun 8. Review.

PMID:
16844268
18.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group.

Lancet. 2006 Apr 15;367(9518):1247-55.

19.

Social and psychological impact of HPV testing in cervical screening: a qualitative study.

McCaffery K, Waller J, Nazroo J, Wardle J.

Sex Transm Infect. 2006 Apr;82(2):169-74.

20.

Supplemental Content

Support Center